| |
Offered incentive (N = 481)
|
Not offered incentive (N = 534)
|
|---|
|
Age (mean, SD)
|
66.2 (10.2)
|
66.3 (9.6)
|
|
Sex
| | |
|
Male
|
281 (58.4)
|
308 (57.7)
|
|
Female
|
162 (33.7)
|
182 (34.1)
|
|
Unknown
|
38 (7.9)
|
44 (8.2)
|
|
SIMD deprivation categoryb
| | |
|
1–3 (least deprived)
|
138 (28.7)
|
134 (25.1)
|
|
4–7
|
242 (50.3)
|
274 (51.4)
|
|
8–10 (most deprived)
|
101 (21.0)
|
125 (23.5)
|
|
Geographic areasb
| | |
|
Angus and Dundee
|
217 (45.1)
|
215 (40.3)
|
|
Fife
|
200 (41.6)
|
234 (43.9)
|
|
Perth
|
64 (13.3)
|
84 (15.8)
|
|
Target patient group
| | |
|
FAST
|
158 (32.9)
|
174 (32.6)
|
|
SCOT
|
84 (17.5)
|
97 (18.2)
|
|
PATHWAY 1
|
46 (9.6)
|
47 (8.8)
|
|
PATHWAY 2
|
101 (21.0)
|
109 (20.4)
|
|
PATHWAY 3
|
92 (19.1)
|
107 (20.0)
|
- aFAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial; SIMD, SD, Standard deviation; Scottish Index of Multiple Deprivation. Data are mean (SD) or number (%). There were no significant differences between groups bIncludes one patient with missing data.
